These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 30753470)
41. Isolation, speciation and antifungal susceptibility testing of Candida isolates from various clinical specimens at a tertiary care hospital, Nepal. Khadka S; Sherchand JB; Pokhrel BM; Parajuli K; Mishra SK; Sharma S; Shah N; Kattel HP; Dhital S; Khatiwada S; Parajuli N; Pradhan M; Rijal BP BMC Res Notes; 2017 Jun; 10(1):218. PubMed ID: 28646915 [TBL] [Abstract][Full Text] [Related]
42. Population structure and molecular genetic characterization of clinical Candida tropicalis isolates from a tertiary-care hospital in Kuwait reveal infections with unique strains. Al-Obaid K; Asadzadeh M; Ahmad S; Khan Z PLoS One; 2017; 12(8):e0182292. PubMed ID: 28854190 [TBL] [Abstract][Full Text] [Related]
43. Rapid identification and susceptibility testing of Candida spp. from positive blood cultures by combination of direct MALDI-TOF mass spectrometry and direct inoculation of Vitek 2. Idelevich EA; Grunewald CM; Wüllenweber J; Becker K PLoS One; 2014; 9(12):e114834. PubMed ID: 25489741 [TBL] [Abstract][Full Text] [Related]
44. Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002. Wang JL; Chang SC; Hsueh PR; Chen YC J Microbiol Immunol Infect; 2004 Aug; 37(4):236-41. PubMed ID: 15340652 [TBL] [Abstract][Full Text] [Related]
45. The A395T mutation in ERG11 gene confers fluconazole resistance in Candida tropicalis causing candidemia. Tan J; Zhang J; Chen W; Sun Y; Wan Z; Li R; Liu W Mycopathologia; 2015 Apr; 179(3-4):213-8. PubMed ID: 25398256 [TBL] [Abstract][Full Text] [Related]
46. Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrata. Vella A; De Carolis E; Mello E; Perlin DS; Sanglard D; Sanguinetti M; Posteraro B Sci Rep; 2017 Aug; 7(1):9099. PubMed ID: 28831086 [TBL] [Abstract][Full Text] [Related]
47. MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole. Marinach C; Alanio A; Palous M; Kwasek S; Fekkar A; Brossas JY; Brun S; Snounou G; Hennequin C; Sanglard D; Datry A; Golmard JL; Mazier D Proteomics; 2009 Oct; 9(20):4627-31. PubMed ID: 19750514 [TBL] [Abstract][Full Text] [Related]
48. Identification of Azole Resistance Markers in Clinical Isolates of Candida tropicalis Using cDNA-AFLP Method. Kanani A; Zaini F; Kordbacheh P; Falahati M; Rezaie S; Daie R; Farahyar S; Safara M; Fateh R; Faghihloo E; Fattahi A; Heidari M J Clin Lab Anal; 2016 May; 30(3):266-72. PubMed ID: 25873256 [TBL] [Abstract][Full Text] [Related]
49. Clonality of Fluconazole-Nonsusceptible Candida tropicalis in Bloodstream Infections, Taiwan, 2011-2017. Chen PY; Chuang YC; Wu UI; Sun HY; Wang JT; Sheng WH; Lo HJ; Wang HY; Chen YC; Chang SC Emerg Infect Dis; 2019 Sep; 25(9):1660-1667. PubMed ID: 31441426 [TBL] [Abstract][Full Text] [Related]
50. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
51. Antifungal susceptibility testing of Candida tropicalis biofilms against fluconazole using calorimetric indicator resazurin. Punithavathy PM; Nalina K; Menon T Indian J Pathol Microbiol; 2012; 55(1):72-4. PubMed ID: 22499305 [TBL] [Abstract][Full Text] [Related]
52. Influence of different susceptibility testing methods and media on determination of the relevant fluconazole minimum inhibitory concentrations for heavy trailing Candida isolates with low-high phenotype. Alp S; Sancak B; Hascelik G; Arikan S Mycoses; 2010 Nov; 53(6):475-80. PubMed ID: 19563491 [TBL] [Abstract][Full Text] [Related]
53. Carbon substrates promotes stress resistance and drug tolerance in clinical isolates of Candida tropicalis. Khamrai A; Paul S; Rudramurthy SM; Ghosh AK Arch Microbiol; 2024 May; 206(6):270. PubMed ID: 38767668 [TBL] [Abstract][Full Text] [Related]
54. [Susceptibility to fluconazole of clinical interest yeasts: new breakpoints]. García-Agudo L; García-Martos P; Marín-Casanova P; Rodríguez-Iglesias M Rev Esp Quimioter; 2012 Dec; 25(4):266-8. PubMed ID: 23303258 [TBL] [Abstract][Full Text] [Related]
55. Rezafungin Helleberg M; Jørgensen KM; Hare RK; Datcu R; Chowdhary A; Arendrup MC Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015032 [TBL] [Abstract][Full Text] [Related]
56. Five-Year National Surveillance of Invasive Candidiasis: Species Distribution and Azole Susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study. Xiao M; Sun ZY; Kang M; Guo DW; Liao K; Chen SC; Kong F; Fan X; Cheng JW; Hou X; Zhou ML; Li Y; Yu SY; Huang JJ; Wang H; Xu YC; J Clin Microbiol; 2018 Jul; 56(7):. PubMed ID: 29743305 [TBL] [Abstract][Full Text] [Related]
57. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. Tortorano AM; Rigoni AL; Biraghi E; Prigitano A; Viviani MA; J Antimicrob Chemother; 2003 Oct; 52(4):679-82. PubMed ID: 12951345 [TBL] [Abstract][Full Text] [Related]
58. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp]. Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462 [TBL] [Abstract][Full Text] [Related]
59. Selection and evaluation of appropriate reference genes for RT-qPCR based expression analysis in Candida tropicalis following azole treatment. Paul S; Singh S; Chakrabarti A; Rudramurthy SM; Ghosh AK Sci Rep; 2020 Feb; 10(1):1972. PubMed ID: 32029802 [TBL] [Abstract][Full Text] [Related]
60. In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines. Testore GP; Dori L; Buonomini AR; Schito GC; Soro O; Fortina G; Andreoni S; Carlone N; Tullio V; Andreoni M Diagn Microbiol Infect Dis; 2004 Nov; 50(3):187-92. PubMed ID: 15541604 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]